Sangam: A Confluence of Knowledge Streams

Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis

Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis

Rule, S; Dreyling, M; Goy, A; Hess, G; Auer, R; Kahl, B; Hernández-Rivas, J-Á; Qi, K; Deshpande, S; Parisi, L; Wang, M
URI: http://localhost:8080/xmlui/handle/CUHPOERS/228964

Show full item record

Files in this item

Files Size Format View
8911-Article Text-63824-1-10-20200724.pdf 553.8Kb application/pdf View/Open

This item appears in the following Collection(s)

Search DSpace


Advanced Search

Browse